Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction

CNS Spectrums

Volumn 19, Issue 2, 2014, Pages 121-133

  Pehrson, Alan L ^a   Sanchez, Connie ^a  

^a LUNDBECK RESEARCH USA   (United States)

Author keywords

glutamate; metabotropic glutamate receptors (mGluRs); N methyl D aspartate (NMDA); selective serotonin reuptake inhibitor (SSRI); serotonin (5 HT); serotonin transporter (SERT); vilazodone; vortioxetine; Amino 3 hydroxy 5 methyl 4 isoxazole propionic acid (AMPA)

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANIRACETAM; ANTIDEPRESSANT AGENT; GLUTAMIC ACID; GLYX13; KETAMINE; LAMOTRIGINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N [2 [4 (3 THIENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; RILUZOLE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN TRANSPORTER; TRAXOPRODIL; UNCLASSIFIED DRUG; VILAZODONE; VORTIOXETINE; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; GLUTAMATE RECEPTOR; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2 ANTAGONIST; METABOTROPIC RECEPTOR 3 ANTAGONIST; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MONOAMINE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SEROTONIN; SEROTONIN RECEPTOR AFFECTING AGENT;

ARTICLE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; IC 50; NEUROMODULATION; NEUROTRANSMISSION; PRIORITY JOURNAL; RECEPTOR BLOCKING; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; DRUG EFFECT; DRUG RESEARCH; NONHUMAN; PROTEIN FUNCTION; REVIEW; TREATMENT RESPONSE; ANIMAL; METABOLISM; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; COGNITION DISORDERS; DEPRESSION; GLUTAMIC ACID; HUMANS; SEROTONIN; SEROTONIN AGENTS; SYNAPTIC TRANSMISSION;

EID: 84901720404     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000540     Document Type: Article

References (153)

1. Stahl SM. Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr. 2010; 15(2): 79-94.
2. Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets. 2006; 7(2): 139-147.
3. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A metaanalysis of placebo-controlled randomized trials. Am J Psychiatry. 2009; 166(9): 980-991.
4. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry. 2001; 178: 200-206. (Pubitemid 32183601)
5. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-Analysis of cognitive deficits in firstepisode major depressive disorder. J Affect Disord. 2012; 140(2): 113-124.
6. Mathews A, MacLeod C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol. 2005; 1: 167-195. (Pubitemid 43843950)
7. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review. J Affect Disord. 2011; 134(1-3): 20-31.
8. Naismith SL, Longley WA, Scott EM, Hickie IB. Disability in major depression related to self-rated and objectively-measured cognitive deficits: A preliminary study. BMC Psychiatry. 2007; 7: 32-38.
9. Altamura CA, Mauri MC, Ferrara A, et al. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993; 150(11): 1731-1733. (Pubitemid 23325960)
10. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr. 1982; 232(4): 299-304. (Pubitemid 13124834)
11. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand. 1998; 97(4): 302-308. (Pubitemid 28179268)
12. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry. 2000; 47(7): 586-593. (Pubitemid 30169251)
13. Pangalos MN, Malizia AL, Francis PT, et al. Effect of psychotropic drugs on excitatory amino acids in patients undergoing psychosurgery for depression. Br J Psychiatry. 1992; 160: 638-642.
14. Francis PT, Poynton A, Lowe SL, et al. Brain amino acid concentrations and Ca21-dependent release in intractable depression assessed antemortem. Brain Res. 1989; 494(2): 315-324. (Pubitemid 19194545)
15. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007; 62(11): 1310-1316. (Pubitemid 350060893)
16. Yuksel C, Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry. 2010; 68(9): 785-794.
17. Beneyto M, Meador-Woodruff JH. Lamina-specific abnormalities of NMDA receptor-Associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology. 2008; 33(9): 2175-2186. (Pubitemid 351992080)
18. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology. 2007; 32(9): 1888-1902. (Pubitemid 47258508)
19. Bleakman D, Alt A, Witkin JM. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets. 2007; 6(2): 117-126. (Pubitemid 46681772)
20. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008; 33(9): 2080-2092. (Pubitemid 351992096)
21. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets. 2005; 9(1): 153-168. (Pubitemid 40331202)
22. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012; 62(1): 63-77.
23. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(7): 1558-1568.
24. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009; 30(11): 563-569.
25. Schloss P, Williams DC. The serotonin transporter: A primary target for antidepressant drugs. J Psychopharmacol. 1998; 12(2): 115-121. (Pubitemid 28312567)
26. Smythies J. Section V. Serotonin system. Int Rev Neurobiol. 2005; 64: 217-268.
27. Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther. 2013; 137(1): 119-131.
28. Gigliucci V, O'Dowd G, Casey S, et al. Ketamine elicits sustained antidepressant-like activity via a serotonindependent mechanism. Psychopharmacology (Berl). 2013; 228(1): 157-166.
29. Nutt DJ. Beyond psychoanaleptics-can we improve antidepressant drug nomenclature? J Psychopharmacol. 2009; 23(4): 343-345.
30. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Curr Drug Targets. 2013; 14(5): 578-585.
31. Javitt DC, Schoepp D, Kalivas PW, et al. Translating glutamate: from pathophysiology to treatment. Sci Transl Med. 2011; 3(102): 102mr2.
32. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010; 329(5994): 959-964.
33. Catena-Dell'Osso M, Fagiolini A, Rotella F, Baroni S, Marazziti D. Glutamate system as target for development of novel antidepressants. CNS Spectr. In press.
34. McCarthy DJ, Alexander R, Smith MA, et al. Glutamate-based depression GBD. Med Hypotheses. 2012; 78(5): 675-681.
35. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8): 856-864. (Pubitemid 44188478)
36. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective Nmethyl- D-Aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008; 28(6): 631-637.
37. Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006; 163(1): 153-155. (Pubitemid 43050119)
38. Anticevic A, Gancsos M, Murray JD, et al. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A. 2012; 109(41): 16720-16725.
39. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-Amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008; 63(4): 349-352. (Pubitemid 351146651)
40. Tripp A, Oh H, Guilloux JP, Martinowich K, Lewis DA, Sibille E. Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am J Psychiatry. 2012; 169(11): 1194-1202.
41. Murphy SE, Norbury R, O'Sullivan U, Cowen PJ, Harmer CJ. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry. 2009; 194(6): 535-540.
42. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study. Mol Psychiatry. 2008; 13(11): 1011-1020.
43. Knapp RJ, Goldenberg R, Shuck C, et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol. 2002; 440(1): 27-35. (Pubitemid 34312035)
44. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord. 2004; 3(3): 181-194. (Pubitemid 38854913)
45. Hahn CG, Gyulai L, Baldassano CF, Lenox RH. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry. 2004; 65(6): 791-804.
46. Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002; 51(3): 253-260. (Pubitemid 34142637)
47. Normann C, Hummel B, Scharer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: A placebocontrolled, double-blind study. J Clin Psychiatry. 2002; 63(4): 337-344. (Pubitemid 34456362)
48. Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004; 161(1): 171-174. (Pubitemid 38419327)
49. Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry. 2004; 161(11): 2132.
50. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol. 2007; 17(3): 172-179. (Pubitemid 44779190)
51. Chaki S, Yoshikawa R, Hirota S, et al. MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology. 2004; 46(4): 457-467. (Pubitemid 38224431)
52. Higgins GA, Ballard TM, Kew JN, et al. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology. 2004; 46(7): 907-917. (Pubitemid 38471944)
53. Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res. 2003; 140(1-2): 1-47. (Pubitemid 36313239)
54. Teixeira CM, Pomedli SR, Maei HR, Kee N, Frankland PW. Involvement of the anterior cingulate cortex in the expression of remote spatial memory. J Neurosci. 2006; 19(29): 7555-7564. (Pubitemid 44315175)
55. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology. 2004; 29(7): 1259-1269. (Pubitemid 38780649)
56. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl). 2004; 174(1): 39-44. (Pubitemid 38925089)
57. Hamlyn E, Brand L, Shahid M, Harvey BH. The ampakine, Org 26576, bolsters early spatial reference learning and retrieval in the Morris water maze: A subchronic, dose-ranging study in rats. Behav Pharmacol. 2009; 20(7): 662-667.
58. Fowler SW,Walker JM, Klakotskaia D, et al. Effects of a metabotropic glutamate receptor 5 positive allosteric modulator, CDPPB, on spatial learning task performance in rodents. Neurobiol Learn Mem. 2013; 99: 25-31.
59. Ozawa T, Kumeji M, Yamada K, Ichitani Y. D-Cycloserine enhances spatial memory in spontaneous place recognition in rats. Neurosci Lett. 2012; 509(1): 13-16.
60. Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci. 1987; 7(2): 357-368. (Pubitemid 17017465)
61. Zajaczkowski W, Frankiewicz T, Parsons CG, Danysz W. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology. 1997; 36(7): 961-971. (Pubitemid 27300126)
62. Sprouse JS, Aghajanian GK. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse. 1987; 1(1): 3-9. (Pubitemid 17114243)
63. Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessivecompulsive and panic disorders. Neuropsychopharmacology. 1999; 21(2 suppl): 91S-98S. (Pubitemid 29396476)
64. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology. 2005; 30(7): 1269-1277. (Pubitemid 40848081)
65. Kennett GA, Dourish CT, Curzon G. Antidepressantlike action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol. 1987; 134(3): 265-274. (Pubitemid 17033932)
66. Robinson DS, Rickels K, Feighner J, et al. Clinical effects of the 5-HT1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol. 1990; 10(3 suppl): 67S-76S. (Pubitemid 20212933)
67. Martinez D, Hwang D, Mawlawi O, et al. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: A dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology. 2001; 24(3): 209-229. (Pubitemid 32146193)
68. Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex. 2004; 14(10): 1100-1109. (Pubitemid 39258165)
69. Aznar S, Qian Z, Shah R, Rahbek B, Knudsen GM. The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res. 2003; 959(1): 58-67. (Pubitemid 35435406)
70. Luscher C, Jan LY, Stoffel M, Malenka RC, Nicoll RA. G protein-coupled inwardly rectifying K1 channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron. 1997; 19(3): 687-695. (Pubitemid 27430754)
71. Llado-Pelfort L, Santana N, Ghisi V, Artigas F, Celada P. 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb Cortex. 2012; 22(7): 1487-1497.
72. Llado-Pelfort L, Assie MB, Newman-Tancredi A, Artigas F, Celada P. Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. Br J Pharmacol. 2010; 160(8): 1929-1940.
73. Wang S, Zhang QJ, Liu J, et al. The firing activity of pyramidal neurons in medial prefrontal cortex and their response to 5-hydroxytryptamine-1A receptor stimulation in a rat model of Parkinson's disease. Neuroscience. 2009; 162(4): 1091-1100.
74. Levkovitz Y, Segal M. Serotonin 5-HT1A receptors modulate hippocampal reactivity to afferent stimulation. J Neurosci. 1997; 17(14): 5591-5598. (Pubitemid 27300323)
75. Newman-Tancredi A, Martel JC, Assie MB, et al. Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol. 2009; 156(2): 338-353.
76. Depoortere R, Auclair AL, Bardin L, et al. F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur Neuropsychopharmacol. 2010; 20(9): 641-654.
77. Meneses A, Hong E. 5-HT1A receptors modulate the consolidation of learning in normal and cognitively impaired rats. Neurobiol Learn Mem. 1999; 71(2): 207-218. (Pubitemid 29397969)
78. Herremans AH, Hijzen TH, Olivier B, Slangen JL. Serotonergic drug effects on a delayed conditional discrimination task in the rat; involvement of the 5-HT1A receptor in working memory. J Psychopharmacol. 1995; 9(3): 242-250.
79. Tsuji M, Takeda H, Matsumiya T. Modulation of passive avoidance in mice by the 5-HT1A receptor agonist flesinoxan: comparison with the benzodiazepine receptor agonist diazepam. Neuropsychopharmacology. 2003; 28(4): 664-674.
80. Horiguchi M, Meltzer HY. The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl). 2012; 221(2): 205-215.
81. Sari Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004; 28(6): 565-582. (Pubitemid 39446482)
82. Peddie CJ, Davies HA, Colyer FM, Stewart MG, Rodriguez JJ. A subpopulation of serotonin 1B receptors colocalize with the AMPA receptor subunit GluR2 in the hippocampal dentate gyrus. Neurosci Lett. 2010; 485(3): 251-255.
83. Peddie CJ, Davies HA, Colyer FM, Stewart MG, Rodriguez JJ. Dendritic colocalisation of serotonin1B receptors and the glutamate NMDA receptor subunit NR1 within the hippocampal dentate gyrus: an ultrastructural study. J Chem Neuroanat. 2008; 36(1): 17-26.
84. Cai X, Kallarackal AJ, Kvarta MD, et al. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat Neurosci. 2013; 16(4): 464-472.
85. Ait AD, Segu L, Naili S, Buhot MC. Serotonin 1B receptor regulation after dorsal subiculum deafferentation. Brain Res Bull. 1995; 38(1): 17-23.
86. Boeijinga PH, Boddeke HW. Activation of 5-HT1B receptors suppresses low but not high frequency synaptic transmission in the rat subicular cortex in vitro. Brain Res. 1996; 721(1-2): 59-65.
87. Mlinar B, Falsini C, Corradetti R. Pharmacological characterization of 5-HT(1B) receptor-mediated inhibition of local excitatory synaptic transmission in the CA1 region of rat hippocampus. Br J Pharmacol. 2003; 138(1): 71-80. (Pubitemid 36194205)
88. Stepien A, Chalimoniuk M, Strosznajder J. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptorevoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices. Cephalalgia. 1999; 19(10): 859-865. (Pubitemid 30062574)
89. Svenningsson P, Chergui K, Rachleff I, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science. 2006; 311(5757): 77-80. (Pubitemid 43063061)
90. Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wojcik E. Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression. Behav Pharmacol. 2004; 15(8): 523-534. (Pubitemid 40075900)
91. Skelin I, Kovacevic T, Sato H, Diksic M. The opposite effect of a 5-HT1B receptor agonist on 5-HT synthesis, as well as its resistant counterpart, in an animal model of depression. Brain Res Bull. 2012; 88(5): 477-486.
92. Redrobe JP, MacSweeney CP, Bourin M. The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol. 1996; 318(2-3): 213-220. (Pubitemid 27046261)
93. Buhot MC, Patra SK, Naili S. Spatial memory deficits following stimulation of hippocampal 5-HT1B receptors in the rat. Eur J Pharmacol. 1995; 285(3): 221-228.
94. Meneses A. Could the 5-HT1B receptor inverse agonism affect learning consolidation? Neurosci Biobehav Rev. 2001; 25(2): 193-201. (Pubitemid 32366747)
95. Eriksson TM, Madjid N, Elvander-Tottie E, et al. Blockade of 5-HT 1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission. Neuropharmacology. 2008; 54(7): 1041-1050.
96. Thompson AJ, Lummis SC. 5-HT3 receptors. Curr Pharm Des. 2006; 12(28): 3615-3630.
97. Puig MV, Santana N, Celada P, Mengod G, Artigas F. In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex. 2004; 14(12): 1365-1375. (Pubitemid 39507287)
98. Morales M, Bloom FE. The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J Neurosci. 1997; 17(9): 3157-3167. (Pubitemid 27175828)
99. Reznic J, Staubli U. Effects of 5-HT3 receptor antagonism on hippocampal cellular activity in the freely moving rat. J Neurophysiol. 1997; 77(1): 517-521. (Pubitemid 27053806)
100. Ashby CR Jr, Minabe Y, Edwards E, Wang RY. 5-HT3- like receptors in the rat medial prefrontal cortex: an electrophysiological study. Brain Res. 1991; 550(2): 181-191.
101. Liang X, Arvanov VL, Wang RY. Inhibition of NMDAreceptor mediated response in the rat medial prefrontal cortical pyramidal cells by the 5-HT3 receptor agonist SR 57227A and 5-HT: Intracellular studies. Synapse. 1998; 29(3): 257-268. (Pubitemid 28267935)
102. Staubli U, Xu FB. Effects of 5-HT3 receptor antagonism on hippocampal theta rhythm, memory, and LTP induction in the freely moving rat. J Neurosci. 1995; 15(3 pt 2): 2445-2452.
103. Sanchez C, Robichaud PJ, Pehrson A, Leiser SC. The effects of the multimodal antidepressant Lu AA21004 on attention and vigilance measured as EEG activity in the rat. Eur Neuropsychopharmacol. 2012; 22(suppl 2): S243-S244.
104. Pitsikas N, Borsini F. Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task. Eur J Pharmacol. 1996; 311(2-3): 115-119. (Pubitemid 26330365)
105. Roychoudhury M, Kulkarni SK. Effects of ondansetron on short-term memory retrieval in mice. Methods Find Exp Clin Pharmacol. 1997; 19(1): 43-46. (Pubitemid 27167763)
106. Pehrson A, Gaarn du Jardin Nielsen K, Jensen JB, Sanchez C. The novel multimodal antidepressant Lu AA21004 improves memory performance in 5-HT depleted rats via 5-HT3 and 5-HT1A receptor mechanisms. Eur Neuropsychopharmacol. 2012; 22(suppl 2): S269-S269.
107. Fontana DJ, Daniels SE, Henderson C, Eglen RM, Wong EH. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology (Berl). 1995; 120(4): 409-417.
108. Carey GJ, Costall B, Domeney AM, et al. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharmacol Biochem Behav. 1992; 42(1): 75-83.
109. Martin P, Gozlan H, Puech AJ. 5-HT3 receptor antagonists reverse helpless behaviour in rats. Eur J Pharmacol. 1992; 212(1): 73-78.
110. Mahesh R, Bhatt S, Devadoss T, et al. Antidepressant potential of 5-HT3 receptor antagonist, N-n-propyl-3- ethoxyquinoxaline-2-carboxamide (6n). J Young Pharm. 2012; 4(4): 235-244.
111. Kos T, Popik P, Pietraszek M, et al. Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol. 2006; 16(4): 297-310.
112. Mørk A, Pehrson A, Tottrup BLT, et al. Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012; 340(3): 666-675.
113. Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci. 2004; 25(9): 481-486. (Pubitemid 39149704)
114. Harsing LG Jr. The pharmacology of the neurochemical transmission in the midbrain raphe nuclei of the rat. Curr Neuropharmacol. 2006; 4(4): 313-339.
115. Duncan MJ, Congleton MR. Neural mechanisms mediating circadian phase resetting by activation of 5-HT(7) receptors in the dorsal raphe: roles of GABAergic and glutamatergic neurotransmission. Brain Res. 2010; 1366: 110-119.
116. Bickmeyer U, Heine M, Manzke T, Richter DW. Differential modulation of I(h) by 5-HT receptors in mouse CA1 hippocampal neurons. Eur J Neurosci. 2002; 16(2): 209-218. (Pubitemid 36160241)
117. Fan LL, Zhang QJ, Liu J, et al. In vivo effect of 5-HT(7) receptor agonist on pyramidal neurons in medial frontal cortex of normal and 6-hydroxydopaminelesioned rats: an electrophysiological study. Neuroscience. 2011; 190: 328-338.
118. Tokarski K, Zahorodna A, Bobula B, Hess G. 5-HT7 receptors increase the excitability of rat hippocampal CA1 pyramidal neurons. Brain Res. 2003; 993(1-2): 230-234. (Pubitemid 37464603)
119. Tokarski K, Kusek M, Hess G. 5-HT7 receptors modulate GABAergic transmission in rat hippocampal CA1 area. J Physiol Pharmacol. 2011; 62(5): 535-540.
120. Bonaventure P, Kelly L, Aluisio L, et al. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther. 2007; 321(2): 690-698. (Pubitemid 46624521)
121. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl). 2009; 206(3): 345-354.
122. Stahl SM. The serotonin-7 receptor as a novel therapeutic target. J Clin Psychiatry. 2010; 71(11): 1414-1415.
123. Meneses A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/ instrumental learning task. Behav Brain Res. 2004; 155(2): 275-282. (Pubitemid 39208910)
124. McLean SL, Woolley ML, Thomas D, Neill JC. Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology (Berl). 2009; 206(3): 403-414.
125. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidineinduced novel object recognition deficit in rats. J Pharmacol Exp Ther. 2011; 338(2): 605-614.
126. Waters KA, Stean TO, Hammond B, et al. Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition. Behav Brain Res. 2012; 228(1): 211-218.
127. Bonaventure P, Aluisio L, Shoblock J, et al. Pharmacological blockade of serotonin 5-HT(7) receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission. PLoS One. 2011; 6(6): e20210.
128. Nikiforuk A. Selective blockade of 5-HT7 receptors facilitates attentional set-shifting in stressed and control rats. Behav Brain Res. 2012; 226(1): 118-123.
129. Heinrich T, Bottcher H, Gericke R, et al. Synthesis and structure-Activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J Med Chem. 2004; 47(19): 4684-4692. (Pubitemid 39195559)
130. Page ME, Cryan JF, Sullivan A, et al. Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3-indolyl)- butyl)-butyl]-1-piperazinyl)-benzofuran- 2-carboxamide (EMD 68843): A combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002; 302(3): 1220-1227. (Pubitemid 34920246)
131. De Paulis T. Drug evaluation: vilazodone-A combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs. 2007; 10(3): 193-201. (Pubitemid 46438428)
132. Guay DR. Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder. Consult Pharm. 2012; 27(12): 857-867.
133. Wang SM, Han C, Lee SJ, Patkar AA, Pae CU. A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. In press.
134. Bang-Andersen B, Ruhland T, JørgensenM, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54(9): 3206-3221.
135. Westrich L, Pehrson A, Zhong H, et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract. 2012; 5(suppl 1): 47-47.
136. Pehrson AL, Cremers T, Betry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013; 23(2): 133-145.
137. Bétry C, Pehrson AL, Etievant A, et al. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism. Int J Neuropsychopharmacol. 2013; 16(5): 1115-1127.
138. Li Y, Pehrson AL, Budac DP, Sanchez C, Gulinello M. A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants. Behav Brain Res. 2012; 234(2): 238-247.
139. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012; 15(5): 589-600.
140. Katona C, Hansen T, Olsen CK. A randomized, doubleblind, placebo-controlled, duloxetine-referenced, fixeddose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27(4): 215-223.
141. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetinereferenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012; 22(7): 482-491.
142. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012; 27(4): 197-207.
143. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012; 26(11): 1408-1416.
144. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012; 73(7): 953-959.
145. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012; 28(10): 1717-1724.
146. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29(3): 217-226.
147. Jain R,Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013; 16(2): 313-321.
148. Mørk A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013; 105C: 41-50.
149. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47(4): 351-354. (Pubitemid 30109248)
150. Koliaki CC, Messini C, Tsolaki M. Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: A comparative open study. CNS Neurosci Ther. 2012; 18(4): 302-312.
151. Li X, Tizzano JP, Griffey K, et al. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology. 2001; 40(8): 1028-1033. (Pubitemid 32530609)
152. Bespalov AY, van Gaalen MM, Sukhotina IA, et al. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol. 2008; 592(1-3): 96-102.
153. Burgdorf J, Zhang XL, Nicholson KL, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects